SAMPLE project 1
Egis has already been producing, distributing and promoting Sorbifer in 18 CEE and CIS markets since 1985 under a licence agreement with AstraZeneca. The product has become one of the major brands of Egis, the fifth largest of the company with EUR 20 million turnover per year.
START DATE: 2017-08-04
Target
Egis has already been producing, distributing and promoting Sorbifer in 18 CEE and CIS markets since 1985 under a licence agreement with AstraZeneca. The product has become one of the major brands of Egis, the fifth largest of the company with EUR 20 million turnover per year. Sorbifer is a prescription drug for the prevention and treatment of iron deficiency anemia, which has a strong position in the CEE and CIS markets, particularly in Russia and Poland. We have been present in 18 countries for quite a while with this acknowledged, high quality medicine. Thanks to its very positive perception among physicians and according to our plans, Sorbifer will contribute to the health of even more people in the future. – stated dr. István Hodász, CEO of Egis Pharmaceuticals PLC. As he explained, the current transaction is part of the company’s growth and acquisition strategy in key markets. Within the frame of this strategy Egis has already announced two successful acquisitions in 2017: D-Panthenol and a women’s health product portfolio in Russia.Results
Egis has already been producing, distributing and promoting Sorbifer in 18 CEE and CIS markets since 1985 under a licence agreement with AstraZeneca. The product has become one of the major brands of Egis, the fifth largest of the company with EUR 20 million turnover per year. Sorbifer is a prescription drug for the prevention and treatment of iron deficiency anemia, which has a strong position in the CEE and CIS markets, particularly in Russia and Poland. We have been present in 18 countries for quite a while with this acknowledged, high quality medicine. Thanks to its very positive perception among physicians and according to our plans, Sorbifer will contribute to the health of even more people in the future. – stated dr. István Hodász, CEO of Egis Pharmaceuticals PLC. As he explained, the current transaction is part of the company’s growth and acquisition strategy in key markets. Within the frame of this strategy Egis has already announced two successful acquisitions in 2017: D-Panthenol and a women’s health product portfolio in Russia.Description
Egis has already been producing, distributing and promoting Sorbifer in 18 CEE and CIS markets since 1985 under a licence agreement with AstraZeneca. The product has become one of the major brands of Egis, the fifth largest of the company with EUR 20 million turnover per year.
Sorbifer is a prescription drug for the prevention and treatment of iron deficiency anemia, which has a strong position in the CEE and CIS markets, particularly in Russia and Poland.
We have been present in 18 countries for quite a while with this acknowledged, high quality medicine. Thanks to its very positive perception among physicians and according to our plans, Sorbifer will contribute to the health of even more people in the future. – stated dr. István Hodász, CEO of Egis Pharmaceuticals PLC.
As he explained, the current transaction is part of the company’s growth and acquisition strategy in key markets. Within the frame of this strategy Egis has already announced two successful acquisitions in 2017: D-Panthenol and a women’s health product portfolio in Russia.
Your browser is out of date. Please, use an updated version!